In pancreatic adenocarcinoma cohort from TCGA database, a borderline better OS was mentioned to be in patients with high expression of JMJD3 than those with low expression of JMJD3 (P = 0.11) (Chandrashekar et al., 2017). The gene discussed is KDM6B; the disease is pancreatic adenocarcinoma.